CAS 1181562-87-7 | BELOR-002 : Beloranib

CAS 1181562-87-7 | BELOR-002 : Beloranib
(World's Largest Pharmaceutical Supplier)

  • CAS Number: 1181562-87-7
  • Stock: 999g
  • Assay: 0.00%

Abstract:


CAS 1181562-87-7 is an organic compound with a molecular formula of C18H18N2O2. It is commonly used in pharmaceutical research as a potential treatment for various diseases. This article will provide an overview of the properties and potential applications of CAS 1181562-87-7.


1. Chemical Properties:


CAS 1181562-87-7 has a molecular weight of 298.35 g/mol and a melting point of 180-182°C. It is soluble in organic solvents such as methanol and dichloromethane but insoluble in water. The compound has a purity of 98% or higher.


2. Potential Applications:


CAS 1181562-87-7 has been identified as a potential treatment for several diseases. In particular, it has been studied as a potential treatment for cancer, Alzheimer's disease, and Parkinson's disease. The compound has also shown promise as an anti-inflammatory agent and as a treatment for cardiovascular disease.


3. Mechanism of Action:


The exact mechanism of action of CAS 1181562-87-7 is not fully understood. However, it is believed to work by inhibiting certain enzymes and signaling pathways that are involved in disease progression. For example, it has been shown to inhibit the activity of a protein called PAK1, which is involved in the development of cancer.


4. Preclinical Studies:


Several preclinical studies have been conducted to investigate the potential of CAS 1181562-87-7 as a treatment for various diseases. These studies have generally shown promising results, suggesting that the compound may be effective in treating certain types of cancer as well as Alzheimer's and Parkinson's disease. However, further research is needed to determine the safety and efficacy of the compound in humans.

In conclusion, CAS 1181562-87-7 is a promising compound with potential applications in the treatment of several diseases. While further research is needed to fully understand the mechanism of action and potential side effects of the compound, preclinical studies have shown promising results.